News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
110,006 Results
Type
Article (16684)
Company Profile (25)
Press Release (93283)
Multimedia
Podcasts (160)
Webinars (17)
Section
Business (31584)
Career Advice (1013)
Deals (5889)
Drug Delivery (80)
Drug Development (13512)
Employer Resources (152)
FDA (2744)
Job Trends (3873)
News (53623)
Policy (5074)
Tag
Academia (665)
Academic (1)
Accelerated approval (9)
Adcomms (10)
Allergies (21)
Alliances (8042)
ALS (28)
Alzheimer's disease (408)
Antibody-drug conjugate (ADC) (80)
Approvals (2663)
Artificial intelligence (162)
Autoimmune disease (15)
Automation (2)
Bankruptcy (65)
Best Places to Work (2058)
BIOSECURE Act (12)
Biosimilars (55)
Biotechnology (14)
Bladder cancer (49)
Brain cancer (21)
Breast cancer (89)
Cancer (813)
Cardiovascular disease (113)
Career advice (878)
Career pathing (32)
CAR-T (65)
CDC (24)
Cell therapy (177)
Cervical cancer (9)
Clinical research (10648)
Collaboration (309)
Company closure (1)
Compensation (58)
Complete response letters (16)
COVID-19 (681)
CRISPR (21)
C-suite (156)
Cystic fibrosis (38)
Data (747)
Decentralized trials (2)
Denatured (59)
Depression (39)
Diabetes (110)
Diagnostics (1126)
Digital health (8)
Diversity (9)
Diversity, equity & inclusion (42)
Drug discovery (71)
Drug pricing (70)
Drug shortages (24)
Duchenne muscular dystrophy (67)
Earnings (8171)
Editorial (38)
Employer branding (22)
Employer resources (127)
Events (12872)
Executive appointments (282)
FDA (3124)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (301)
Gene editing (49)
Generative AI (19)
Gene therapy (178)
GLP-1 (438)
Government (1099)
Grass and pollen (2)
Guidances (61)
Healthcare (3335)
HIV (8)
Huntington's disease (12)
IgA nephropathy (21)
Immunology and inflammation (95)
Immuno-oncology (11)
Indications (11)
Infectious disease (737)
Inflammatory bowel disease (38)
Inflation Reduction Act (11)
Influenza (5)
Intellectual property (23)
Interviews (156)
IPO (1805)
IRA (31)
Job creations (1762)
Job search strategy (745)
Kidney cancer (2)
Labor market (66)
Layoffs (281)
Leadership (18)
Legal (1118)
Liver cancer (21)
Longevity (7)
Lung cancer (157)
Lymphoma (34)
Machine learning (12)
Management (43)
Manufacturing (197)
MASH (34)
Medical device (2174)
Medtech (2176)
Mergers & acquisitions (4243)
Metabolic disorders (401)
Multiple sclerosis (18)
NASH (11)
Neurodegenerative disease (66)
Neuropsychiatric disorders (24)
Neuroscience (639)
NextGen: Class of 2025 (1666)
Non-profit (875)
Now hiring (46)
Obesity (238)
Opinion (159)
Ovarian cancer (10)
Pain (36)
Pancreatic cancer (25)
Parkinson's disease (42)
Partnered (13)
Patents (69)
Patient recruitment (44)
Peanut (8)
People (11209)
Pharmaceutical (6)
Pharmacy benefit managers (7)
Phase I (2921)
Phase II (4397)
Phase III (4733)
Pipeline (548)
Policy (160)
Postmarket research (346)
Preclinical (1217)
Press Release (33)
Prostate cancer (41)
Psychedelics (33)
Radiopharmaceuticals (79)
Rare diseases (225)
Real estate (2592)
Recruiting (54)
Regulatory (3551)
Reports (51)
Research institute (608)
Resumes & cover letters (164)
RNA editing (9)
RSV (19)
Schizophrenia (37)
Series A (75)
Series B (38)
Service/supplier (3)
Sickle cell disease (20)
Special edition (25)
Spinal muscular atrophy (32)
Sponsored (19)
Startups (1121)
State (1)
Stomach cancer (5)
Supply chain (29)
Tariffs (26)
The Weekly (99)
Vaccines (315)
Venture capital (46)
Weight loss (208)
Women's health (26)
Worklife (19)
Date
Today (24)
Last 7 days (96)
Last 30 days (456)
Last 365 days (6174)
2025 (4422)
2024 (6880)
2023 (7091)
2022 (11235)
2021 (11705)
2020 (9937)
2019 (8573)
2018 (6287)
2017 (6275)
2016 (5972)
2015 (6751)
2014 (4389)
2013 (2714)
2012 (2730)
2011 (3079)
2010 (2395)
Location
Africa (350)
Alabama (9)
Arizona (21)
Arkansas (1)
Asia (5838)
Australia (1019)
California (1312)
Canada (305)
China (151)
Colorado (53)
Connecticut (57)
Delaware (36)
Europe (18754)
Florida (243)
Georgia (80)
Idaho (10)
Illinois (150)
India (16)
Indiana (81)
Iowa (8)
Japan (44)
Kansas (18)
Kentucky (4)
Louisiana (4)
Maine (3)
Maryland (140)
Massachusetts (1066)
Michigan (69)
Minnesota (75)
Mississippi (1)
Missouri (11)
Montana (4)
Nebraska (7)
Nevada (19)
New Hampshire (9)
New Jersey (488)
New Mexico (11)
New York (336)
North Carolina (210)
North Dakota (2)
Northern California (612)
Ohio (32)
Oklahoma (3)
Oregon (20)
Pennsylvania (259)
Puerto Rico (2)
Rhode Island (7)
South America (411)
South Carolina (8)
South Dakota (1)
Southern California (488)
Tennessee (17)
Texas (202)
United States (5036)
Utah (44)
Virginia (49)
Washington D.C. (11)
Washington State (84)
West Virginia (3)
Wisconsin (17)
110,006 Results for "chiesi farmaceutici spa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
April 12, 2023
·
3 min read
Deals
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
January 8, 2023
·
12 min read
Business
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
May 6, 2024
·
9 min read
Press Releases
Acarpia Farmaceutici and EarlyHealth Group Expand Their Partnership to Improve Access in CARICOM and Mexico
August 28, 2025
·
1 min read
Bio NC
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024.
May 16, 2024
·
6 min read
Business
Nemysis Limited Announces a Strategic Alliance With Bruno Farmaceutici S.p.A.
Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.
November 8, 2023
·
2 min read
Press Releases
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
September 10, 2025
·
3 min read
Deals
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.
March 22, 2023
·
6 min read
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
Chiesi Farmaceutici S.p.A and Haisco Pharmaceutical Group Co.Ltd announced the execution of a Licensing Agreement to develop, manufacture, and commercialise outside China and adjacent territories HSK31858, a novel, reversible dipeptidyl peptidase 1 inhibitor for respiratory diseases.
November 20, 2023
·
2 min read
Press Releases
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
June 19, 2025
·
5 min read
1 of 11,001
Next
